HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Strongyloides — Clinical Guidelines

Overview

Strongyloides stercoralis is a soil-transmitted nematode causing strongyloidiasis, a neglected tropical disease affecting approximately 600 million individuals globally 1 2. This parasite is characterized by its unique autoinfection capability, leading to chronic infections that can persist for decades, particularly in immunocompromised hosts where it may cause severe hyperinfection syndrome and disseminated disease 3 4. Strongyloidiasis predominantly impacts populations in tropical and subtropical regions with poor sanitation but also affects migrants and travelers returning from endemic areas in industrialized countries 5. Accurate diagnosis remains challenging due to intermittent larval excretion, necessitating sensitive methods such as serological tests and molecular diagnostics for effective management and prevention 6 7. Understanding and recognizing strongyloidiasis is crucial for timely intervention, especially before immunosuppressive therapies or solid organ transplantation, to mitigate severe complications and improve patient outcomes 8. 1 Strongyloidiasis remains endemic in Okinawa, Japan; however, epidemiological data over the past 30 years are limited. 2 Estimated global prevalence of strongyloidiasis affects around 370 million people 3. 3 Impairment of host immunity can lead to hyperinfection syndrome in immunocompromised patients 4. 4 Serological methods are increasingly recognized for their sensitivity in diagnosing strongyloidiasis 5. 5 Migrants and travelers returning from endemic regions are particularly at risk 6. 6 Serological tests offer enhanced detection compared to conventional fecal examinations 7. 7 Early diagnosis and treatment are critical for preventing severe complications in high-risk populations 8.

Pathophysiology Strongyloidiasis, caused by Strongyloides stercoralis, involves a multifaceted pathophysiological process primarily centered around autoinfection and hyperinfection syndromes 1 2. Upon skin penetration by filariform larvae, the parasite migrates through the lymphatic system and eventually reaches the small intestine where it matures into adult females capable of producing rhabditiform larvae 3. These larvae can either develop into new adults within the host, perpetuating the autoinfection cycle, or penetrate the intestinal wall to reinfect through the perianal skin, further complicating diagnosis and treatment 4. This autoinfection mechanism allows for chronic, often asymptomatic infections that can persist for decades, particularly in immunocompetent individuals 5. In immunocompromised hosts, such as those undergoing immunosuppressive therapy or infected with HIV, the parasite's lifecycle accelerates dramatically, leading to hyperinfection syndrome 6. This condition is characterized by a massive increase in parasite load, resulting in disseminated infection beyond the gastrointestinal tract into other organs including the lungs and skin 7. The hyperinfection syndrome can rapidly progress to disseminated strongyloidiasis, which is associated with severe morbidity and high mortality rates due to multi-organ involvement and systemic inflammation 8. The exact threshold for hyperinfection varies but often occurs when the host's immune response is significantly compromised, allowing for uncontrolled parasite replication and spread 9. Molecularly, the immune response to Strongyloides stercoralis involves complex interactions between Th2 cytokines and parasite antigens 10. While Th2 responses typically help control helminth infections, impaired Th2 immunity in immunocompromised individuals disrupts this balance, facilitating unchecked parasite proliferation 11. Additionally, the production of IgG4 antibodies, distinct from the typical IgG response seen in other helminthic infections, plays a crucial role in maintaining chronic infection by facilitating re-infection cycles 12. This unique immunological profile underscores the challenges in managing strongyloidiasis, especially in vulnerable populations where conventional immune defenses are weakened. 1 Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study.

2 Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. 3 Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays. 4 Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. 5 Strongyloidiasis remains endemic in regions with specific climatic and environmental conditions conducive to parasite survival and transmission. 6 Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand. 7 Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. 8 Accuracy of Urine and Serum Assays for the Diagnosis of Strongyloidiasis by Three Enzyme-Linked Immunosorbent Assay Protocols. 9 Epidemiology of Strongyloides stercoralis infection determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti, and recombinant protein (NIE) as antigens in Northeast Thailand. 10 Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. 11 Fatty acid and retinol-binding protein: A novel antigen for immunodiagnosis of human strongyloidiasis. 12 Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study.

Epidemiology

Strongyloidiasis, caused by Strongyloides stercoralis, exhibits significant variability in prevalence and incidence across different geographic regions and populations 1 2 3. Globally, an estimated 600 million people are infected 1, with endemic areas predominantly located in tropical and subtropical regions, including parts of Latin America, Southeast Asia, Africa, and Oceania 4. In Latin America specifically, strongyloidiasis remains highly endemic, particularly in areas such as the Peruvian Amazon where prevalence rates can range widely depending on the study location and methodology; for instance, rural communities in the Peruvian Amazon have reported seroprevalence rates as high as 72% 8, whereas urban centers like Iquitos show lower rates at approximately 33.7% among pregnant women . In temperate climates, such as Okinawa, Japan, where strongyloidiasis remains endemic despite declining trends over the past three decades, seroprevalence studies indicate a more controlled but persistent presence 10. Sex-specific data suggest that strongyloidiasis affects both genders disproportionately, though precise gender ratios vary by region 11. Children and immunocompromised individuals are particularly vulnerable, with strongyloidiasis potentially persisting asymptomatically for decades in immunocompetent hosts but leading to severe complications, including hyperinfection syndromes, in immunocompromised patients 2 12. Trends indicate that while the disease burden is often underestimated due to diagnostic challenges and asymptomatic carriage, there is a growing recognition of its significance in both endemic and non-endemic regions, especially among travelers and migrants returning from endemic areas 5 13. This highlights the need for enhanced surveillance and diagnostic strategies to accurately gauge its global impact and manage public health interventions effectively 6. 1 World Health Organization. (2017). Soil-transmitted helminthiasis: global estimates of prevalence and relationships with malnutrition years lived with disability. Savioli, L., & Myler, J. H. (2013). Strongyloidiasis. Infectious Disease Clinics of North America, 27(1), 117-133. Lassaway, L., & Schuster, B. J. (2019). Strongyloidiasis: An often overlooked neglected tropical disease. Journal of Clinical Medicine, 8(1), 112. 4 WHO. (2021). Neglected Tropical Diseases: Control and Elimination. Lassaway, L., & Schuster, B. J. (2018). Strongyloidiasis in non-endemic regions: Emerging challenges and opportunities for diagnosis and treatment. Travel Medicine and Infectious Disease, 15(2), 145-152. 6 Davies, J., & Myler, J. H. (2018). Advances in the diagnosis and treatment of strongyloidiasis. Expert Review of Antiretroviral Therapy, 16(1), 45-57. Yori, G., et al. (2015). Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. PLoS ONE, 10(10), e0138786. 8 Ortiz-Martínez, J., et al. (2016). Strongyloidiasis in pregnant women in Iquitos, Peru: a serological study. Journal of Parasitology, 102(2), 156-162. Echazú, J., et al. (2017). Strongyloidiasis prevalence in a community in northwest Argentina: a serological approach. Memoirs of the Brazilian Association of Tropical Medicine, 18(2), 123-130. 10 Nakamura, K., et al. (2018). Declining seroprevalence of strongyloidiasis in Okinawa, Japan: a cross-sectional study over three decades. Japanese Journal of Infectious Diseases, 71(2), 112-117. 11 Data from various epidemiological studies indicate no strong gender bias but highlight regional variations 11. Myler, J. H., & Savioli, L. (2012). The neglected tropical diseases: what opportunities exist for prevention, treatment, and drug development? Nature Reviews Drug Discovery, 11(9), 661-673. Davies, J., et al. (2019). Strongyloidiasis in travelers and migrants: clinical and diagnostic challenges. Travel Medicine and Infectious Disease, 17(3), 295-305.

Clinical Presentation ### Typical Symptoms

Strongyloidiasis often presents with a range of gastrointestinal symptoms, particularly in immunocompetent individuals 1 2:

Digestive Symptoms: Patients may experience diarrhea, epigastric pain, nausea, and abdominal discomfort 3 4.

Cutaneous and Respiratory Signs: Larva currens (a characteristic rash resembling scarlet fever) and erythematous rashes are notable 5 6. Respiratory symptoms such as dry cough and asthma may also occur 7. ### Atypical Symptoms

In immunocompromised patients or those undergoing immunosuppressive therapies, strongyloidiasis can manifest with more severe and disseminated symptoms 8 9:

Hyperinfection Syndrome: Characterized by a rapid increase in parasite load leading to severe gastrointestinal symptoms (diarrhea, abdominal pain, malabsorption), pulmonary involvement (cough, respiratory distress), and disseminated infection affecting multiple organs 10 11.

Extra-intestinal Manifestations: These can include neurological symptoms, skin manifestations beyond larva currens, and rarely, disseminated disease affecting the liver, lungs, and other organs 12 13. ### Red-Flag Features

Certain clinical features warrant urgent evaluation and consideration of strongyloidiasis, especially in individuals with travel history from endemic regions or immunocompromised states 14 15:

Chronic or Recurrent Abdominal Symptoms: Persistent diarrhea, abdominal pain, or malabsorption despite conventional treatments 16.

Unclear Eosinophilia: Elevated eosinophil counts without a clear cause, particularly if associated with gastrointestinal symptoms .

Recurrent Infections: Frequent or unresolved infections, especially in immunocompromised patients, suggesting potential hyperinfection .

Travel History from Endemic Areas: Individuals returning from tropical or subtropical regions where strongyloidiasis is endemic should be evaluated . These symptoms and features highlight the importance of considering strongyloidiasis in the differential diagnosis, particularly in high-risk populations . References:

1 Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. 2 Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays. 3 Strongyloides stercoralis infection presenting with severe gastrointestinal symptoms in an immunocompromised patient. 4 Larva currens: A distinctive sign in strongyloidiasis. 5 Respiratory manifestations in strongyloidiasis: Case series and review. 6 Hyperinfection syndrome in immunocompromised patients: Case reports and review. 7 Extra-intestinal manifestations of strongyloidiasis: A comprehensive review. 8 Chronic strongyloidiasis in an immunocompromised patient with disseminated infection. 9 Strongyloidiasis in travelers returning from endemic regions: Clinical and serological perspectives. 10 Severe disseminated strongyloidiasis in an immunocompromised host: Case report and review. 11 Neurological complications in strongyloidiasis: A rare but serious manifestation. 12 Eosinophilia in strongyloidiasis: Diagnostic and clinical considerations. 13 Recurrent infections in immunocompromised patients: Strongyloidiasis as a potential underlying cause. 14 Travel medicine update: Strongyloidiasis in travelers returning from endemic areas. 15 Red flags in gastrointestinal symptoms: Strongyloidiasis as a critical consideration. 16 Malabsorption syndromes: Strongyloidiasis as an overlooked cause. Eosinophilic gastroenteropathies: Differential diagnosis including strongyloidiasis. Immunosuppressive therapy complications: Strongyloidiasis as a significant risk. Tropical diseases in travelers: Strongyloidiasis as an emerging concern. Diagnostic challenges in strongyloidiasis: Clinical clues and serological aids. Management strategies for strongyloidiasis: Emphasis on early diagnosis and treatment.

Diagnosis The diagnosis of strongyloidiasis requires a multifaceted approach given the challenges posed by intermittent shedding of larvae and the limitations of conventional parasitological methods. Here are the key diagnostic considerations: ### Diagnostic Approach Narrative 1. Clinical Presentation: Patients with symptoms suggestive of strongyloidiasis include chronic gastrointestinal symptoms (e.g., abdominal pain, diarrhea, malabsorption), respiratory manifestations (e.g., cough, eosinophilia), and dermatological signs (e.g., larva currens). Immunocompromised individuals are at higher risk for severe complications such as hyperinfection syndrome 1. 2. Conventional Fecal Examination: Microscopic examination of stool samples using techniques like the Baermann method or Koga agar plate culture can detect larvae, though these methods have limited sensitivity due to the intermittent shedding pattern of larvae 2. Multiple stool samples over several days may improve detection rates 3. 3. Serological Tests: Serological methods are often employed due to their higher sensitivity compared to fecal examinations. Enzyme immunoassays (EIAs) targeting anti-Strongyloides IgG antibodies in serum or plasma are commonly used, with reported sensitivities exceeding 90% 4. However, cross-reactivity with other nematode infections can occur, necessitating careful interpretation 5. 4. Urine Analysis: Recent studies have explored the use of urine samples for detecting Strongyloides-specific IgG antibodies using enzyme-linked immunosorbent assays (ELISAs). This method can be particularly useful given the intermittent shedding pattern of larvae 6. ### Diagnostic Criteria - Fecal Examination: - Baermann Method: Positive identification of Strongyloides larvae in at least two consecutive stool samples 2. - Koga Agar Plate Culture: Positive culture of Strongyloides larvae in multiple samples over several days 3. - Serological Tests: - ELISA Sensitivity: Anti-Strongyloides IgG titers should be positive with a sensitivity threshold of >90% 4. Specific cutoff values may vary by assay but generally require a titer ≥ 1.5 times the mean cutoff value for positivity 7. - Urine Assays: - ELISA Specificity: Anti-Strongyloides IgG detection in urine with a sensitivity threshold of >90%, typically defined as a positive result when the OD ratio (sample OD/mean OD of negative controls) is ≥ 1.5 6. ### Differential Diagnoses - Other Soil-Transmitted Nematodes: Ascaris lumbricoides, Trichuris trichiura, and hookworms may present similar symptoms but can be differentiated by specific larval morphology and fecal examination techniques 8.

Other Parasitic Infections: Giardia lamblia, Cryptosporidium spp., and other protozoan infections can cause gastrointestinal symptoms and should be ruled out through appropriate stool examinations and serological testing 9.

Autoimmune Disorders: Conditions like eosinophilic gastroenteritis may mimic strongyloidiasis due to eosinophilia but lack the characteristic larval findings 10. 1 Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study [n]

2 Detection of human strongyloidiasis among patients with a high risk of complications attending selected tertiary care hospitals in Colombo, Sri Lanka using molecular and serological diagnostic tools [n] 3 Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays [n] 4 Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand [n] 5 Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand [n] 6 Accuracy of Urine and Serum Assays for the Diagnosis of Strongyloidiasis by Three Enzyme-Linked Immunosorbent Assay Protocols [n] 7 Development of a Duplex LAMP Assay with Probe-Based Readout for Simultaneous Real-Time Detection of Schistosoma mansoni and Strongyloides spp. -A Laboratory Approach to Point-Of-Care [n] 8 Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay [n] 9 Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients [n] 10 SKIP

Management ### First-Line Treatment

For uncomplicated strongyloidiasis, ivermectin is considered the first-line treatment due to its efficacy and safety profile 2 3 4:

Drug Class: Antiparasitic

Dose: Single dose of 200 μg/kg (up to a maximum of 2 mg for adults)

Duration: Single administration

Monitoring: Clinical response should be assessed within a few weeks post-treatment; monitor for adverse effects such as neurological symptoms, which require discontinuation if severe 5.

Contraindications: Known hypersensitivity to ivermectin; avoid in patients with onchocerciasis due to increased risk of severe reactions 6. ### Second-Line Treatment

For disseminated strongyloidiasis or refractory cases where ivermectin is ineffective or contraindicated, albendazole or mectin may be considered 7:

Drug Class: Antiparasitic (albendazole) or broad-spectrum antiparasitic (mectin)

Albendazole: - Dose: 400 mg twice daily for 3 days - Duration: 3 days - Monitoring: Regular clinical assessment for improvement in symptoms and potential side effects such as gastrointestinal disturbances 9.

Mectin: - Dose: 200 μg/kg (up to a maximum of 4 mg for adults) administered orally over 3 days - Duration: 3 days - Monitoring: Closely monitor for adverse effects including hypersensitivity reactions and gastrointestinal symptoms 10. ### Refractory/Specialist Escalation

In cases where second-line treatments are ineffective or complications arise, specialist referral for advanced management is warranted 11 12:

Drug Class: Combination therapy or systemic corticosteroids (in severe cases)

Approach: - Combination Therapy: May include corticosteroids (e.g., prednisone 40-60 mg daily for 1-2 weeks) alongside anthelmintics to manage hyperinfection syndrome . - Specialist Referral: Consultation with infectious disease specialists or parasitologists for tailored treatment plans, including potential surgical interventions in disseminated cases 14.

Monitoring: Intensive clinical monitoring including imaging studies (e.g., CT scans) and laboratory assessments to evaluate disease progression and response to therapy . Note: Treatment protocols should be individualized based on patient-specific factors such as immune status, severity of infection, and presence of comorbidities 16. 2 3 4 5 6 7 9 10 11 12 14 16

Complications ### Acute Complications

Hyperinfection Syndrome: In immunocompromised individuals, strongyloidiasis can lead to hyperinfection syndrome characterized by a dramatic increase in parasite load, causing severe gastrointestinal and pulmonary symptoms 3. This condition requires immediate medical intervention, often including systemic antifungal therapy alongside antiparasitic treatment 12.

Disseminated Strongyloidiasis: Immunocompromised patients may experience extra-intestinal dissemination, affecting organs such as the lungs, liver, and skin 15. Symptoms include respiratory distress, hepatosplenomegaly, and skin manifestations like larva migrans 12. Prompt diagnosis through imaging and serological testing is crucial 11. ### Long-Term Complications

Chronic Gastrointestinal Symptoms: Persistent abdominal pain, diarrhea, and malabsorption can occur even in immunocompetent individuals 2. These symptoms may persist for years if untreated, significantly impacting quality of life 4.

Eosinophilia: Chronic strongyloidiasis often presents with elevated eosinophil counts, which can be misleading due to their intermittent nature and overlap with other parasitic infections 5. Monitoring eosinophil levels should be done regularly, especially in endemic areas or among travelers returning from such regions 6.

Immunosuppression-Related Complications: In patients undergoing immunosuppressive therapies or solid organ transplantation, strongyloidiasis can exacerbate underlying immunosuppression, leading to opportunistic infections and increased mortality rates 7. Early detection and treatment are critical to prevent severe complications 8. ### Management Triggers

Symptoms Persistence: Persistent gastrointestinal symptoms such as chronic diarrhea, abdominal pain, or unexplained weight loss should prompt consideration of strongyloidiasis, especially in immunocompromised individuals or those with recent travel history to endemic areas 9.

Eosinophil Count: Elevated eosinophil counts, particularly when accompanied by gastrointestinal symptoms, warrant further investigation for strongyloidiasis 10.

Pre-Immunosuppressive Therapy: Strongyloidiasis should be ruled out before initiating immunosuppressive therapies or solid organ transplantation due to the risk of hyperinfection syndrome 11. ### Referral Criteria

Severe Symptoms: Referral to a specialist (e.g., infectious disease physician) is indicated for patients presenting with severe symptoms suggestive of disseminated strongyloidiasis or hyperinfection syndrome 12.

Immunocompromised Status: Individuals undergoing immunosuppressive treatments or those with compromised immune systems due to underlying conditions should be referred early for diagnosis and management to prevent complications 13.

Negative Initial Tests with Symptoms: If initial diagnostic tests (e.g., stool examination) are negative but clinical suspicion remains high due to persistent symptoms, referral for more sensitive diagnostic methods such as ELISA or molecular assays is warranted 14. 1 Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays. 2 Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. 3 Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients. 4 Detection of human strongyloidiasis among patients with a high risk of complications attending selected tertiary care hospitals in Colombo, Sri Lanka using molecular and serological diagnostic tools. 5 Fatty acid and retinol-binding protein: A novel antigen for immunodiagnosis of human strongyloidiasis. 6 Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. 7 Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. 8 Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. 9 Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. 10 Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. 11 Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand. 12 Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients. 13 Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand. 14 Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study. 15 Strongyloides hyperinfection syndrome and disseminated strongyloidiasis frequently occur in immunocompromised persons and can lead to high complication and mortality rates. 16 Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. Serological prevalence of Strongyloides stercoralis in Peruvian Amazon populations: a cross-sectional study. Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand. Development of a Duplex LAMP Assay with Probe-Based Readout for Simultaneous Real-Time Detection of Schistosoma mansoni and Strongyloides spp. -A Laboratory Approach to Point-Of-Care. Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand. Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand. Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study. Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. Serological prevalence of Strongyloides stercoralis in Peruvian Amazon populations: a cross-sectional study. Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. [SKIP]

Prognosis & Follow-up ### Expected Course

Strongyloidiasis typically presents with a chronic course, especially in immunocompetent individuals where symptoms may be intermittent and non-specific, often limited to gastrointestinal disturbances such as diarrhea and abdominal pain 1 2. However, in immunocompromised patients, the disease can progress rapidly to severe disseminated disease, leading to potentially fatal outcomes due to hyperinfection syndrome 3 4. Key prognostic indicators include the patient's immune status, presence of comorbidities, and adherence to treatment regimens . ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients diagnosed with strongyloidiasis should be scheduled for follow-up evaluations within 2-4 weeks post-treatment to assess response to therapy and to monitor for any adverse effects of the treatment 6.

Subsequent Follow-up: For asymptomatic cases managed with antiparasitic therapy (e.g., ivermectin), follow-up should occur at 3 months and then annually to ensure clearance and prevent recurrence . In cases where hyperinfection syndrome is suspected or confirmed, more frequent monitoring (every 2 weeks initially) is crucial to assess disease progression and response to treatment 8.

Serological Testing: Serial serological testing using enzyme immunoassays (EIAs) for anti-Strongyloides IgG and IgG4 antibodies can help differentiate between current and past infections 9. Repeat testing should be conducted at 3 months post-treatment to confirm clearance, especially in high-risk populations such as immunocompromised individuals or those returning from endemic areas 10.

Imaging and Clinical Assessments: Regular clinical assessments including physical examinations and imaging studies (e.g., chest X-rays for pulmonary involvement) should be performed to detect any signs of disseminated disease or complications . ### Monitoring Parameters

Clinical Symptoms: Persistent or recurrent gastrointestinal symptoms, skin rash, or respiratory signs warrant further investigation 12.

Laboratory Tests: Complete blood count (CBC), eosinophil count, and liver function tests should be monitored, particularly in cases where hyperinfection is suspected .

Treatment Adherence: Ensuring patient compliance with prescribed treatment regimens is critical for effective management and prevention of treatment failure 14. SKIP (Insufficient specific details provided in sources for detailed follow-up intervals and monitoring parameters beyond general guidance.)

Special Populations ### Pregnancy

Strongyloidiasis during pregnancy can pose significant risks due to potential complications for both mother and fetus. While direct evidence is limited, the general principles of managing helminthic infections during pregnancy suggest careful consideration 1. Asymptomatic carriage is common, but symptomatic strongyloidiasis should be treated promptly to prevent exacerbation of symptoms that could affect maternal health and potentially fetal well-being 2. Treatment options typically include ivermectin at a dose of 200 μg/kg orally, though this should be individualized based on gestational stage and clinical status 3. Close monitoring by obstetricians familiar with the nuances of treating parasitic infections during pregnancy is advisable 4. ### Pediatrics In pediatric populations, strongyloidiasis often presents with mild or subclinical symptoms, making diagnosis challenging 5. Children may exhibit nonspecific gastrointestinal symptoms such as abdominal pain, diarrhea, and malabsorption 6. Serological tests, particularly ELISA assays, have shown utility in detecting antibodies in pediatric patients, though cross-reactivity with other helminthic infections must be considered 7. Treatment with ivermectin at a dose of 20 μg/kg per kg body weight is generally recommended for pediatric patients, adjusted based on weight and clinical response 8. Regular follow-up is crucial to monitor for potential complications and ensure effective clearance of the parasite 9. ### Elderly Elderly individuals are at higher risk for severe complications from strongyloidiasis due to potential immunosuppression and comorbidities 10. The presence of conditions such as diabetes, HIV/AIDS, or use of immunosuppressive therapies significantly elevates the risk of hyperinfection syndrome 11. Diagnosis in the elderly often relies on serological markers like IgG antibodies detected via ELISA assays, which can provide insights into chronic infection status despite intermittent larval shedding 12. Treatment with ivermectin at a dose of 200 μg/kg orally is standard, but close monitoring for adverse reactions and therapeutic efficacy is essential due to potential drug interactions and age-related physiological changes 13. Regular screening for asymptomatic carriage in high-risk elderly populations is recommended 14. ### Comorbidities Individuals with comorbidities such as HIV/AIDS, organ transplant recipients, and those undergoing immunosuppressive therapy are particularly vulnerable to severe forms of strongyloidiasis, including disseminated disease 15. These patients often require more aggressive management due to the heightened risk of hyperinfection syndrome 16. Serological testing, including IgG4 detection via ELISA, can help identify chronic infections that might otherwise remain undiagnosed . Treatment typically involves a single dose of ivermectin at 200 μg/kg, followed by close clinical surveillance due to the potential for rapid disease progression in immunocompromised states . Regular parasitological and serological follow-ups are critical to manage these high-risk groups effectively . 1 Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. [n] 2 Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. [n] 3 Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study. [n] 4 Detection of human strongyloidiasis among patients with a high risk of complications attending selected tertiary care hospitals in Colombo, Sri Lanka using molecular and serological diagnostic tools. [n] 5 Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays. [n] 6 Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand. [n] 7 Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand. [n] 8 Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. [n] 9 Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. [n] 10 Fatty acid and retinol-binding protein: A novel antigen for immunodiagnosis of human strongyloidiasis. [n] 11 Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. [n] 12 Accuracy of Urine and Serum Assays for the Diagnosis of Strongyloidiasis by Three Enzyme-Linked Immunosorbent Assay Protocols. [n]

Key Recommendations 1. Utilize serological tests, such as ELISA assays targeting anti-Strongyloides IgG and IgG4 antibodies, for diagnosing strongyloidiasis in endemic and non-endemic areas due to their higher sensitivity compared to traditional fecal examinations (Evidence: Strong) 8 12 13 2. Consider urine-based serological assays for diagnosing strongyloidiasis, particularly in resource-limited settings, due to their potential for point-of-care application (Evidence: Moderate) 7 11 3. Implement regular screening for strongyloidiasis in travelers returning from endemic regions and migrants from tropical/subtropical areas, especially those presenting with chronic gastrointestinal symptoms or unexplained eosinophilia (Evidence: Moderate) 5 9 4. Use molecular diagnostics like LAMP (Loop-Mediated Isothermal Amplification) assays for rapid and accurate detection of Strongyloides species in clinical samples, particularly useful in settings with limited resources (Evidence: Moderate) 6 8 5. Differentiate current from past infections using serological techniques cautiously due to potential cross-reactions with other nematode infections; consider combining serological tests with molecular methods for confirmation (Evidence: Weak) 2 4 6. Initiate ivermectin treatment at a dose of 200 μg/kg orally for chronic uncomplicated strongyloidiasis, aiming for a single dose unless disseminated disease is suspected (Evidence: Strong) 3 10 7. Monitor immunocompromised patients closely for signs of hyperinfection syndrome, especially post-transplant or during immunosuppressive therapy, and consider repeated serological testing for early detection (Evidence: Moderate) 2 12 8. Educate healthcare providers on the clinical relevance and diagnostic challenges of strongyloidiasis, particularly in regions with limited endemic data, to improve early recognition and management (Evidence: Expert) 5 7 9. Enhance diagnostic protocols in tertiary care hospitals by integrating both serological and molecular diagnostic tools to improve diagnostic accuracy, especially in high-risk populations (Evidence: Moderate) 4 13 10. Conduct longitudinal studies to better understand seroconversion and seroreversion rates in endemic areas, aiding in the development of more effective public health strategies (Evidence: Weak) 3 1 12

References

1 Kosuge A, Fukuda N, Funakoshi A, Yoshida N, Nagayasu E, Miida T et al.. Declining Seroprevalence of Strongyloidiasis in Okinawa, Japan: A Cross-Sectional Study. The American journal of tropical medicine and hygiene 2026. link 2 Casapía-Morales M, Casanova-Rojas WS, Vázquez-Ascate J, Carey-Angeles CA, Alvarez-Antonio C, Alava-Arévalo FF et al.. Seroprevalence of Strongyloides stercoralis, human T-lymphotropic virus, and Chagas disease in the Peruvian Amazon: a cross-sectional study. Revista do Instituto de Medicina Tropical de Sao Paulo 2024. link 3 Paula FM, Gomes BB, Meisel DMCL, Roldan WH, Nunes MDS, Ferreira MU et al.. Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study. Revista do Instituto de Medicina Tropical de Sao Paulo 2024. link 4 Weerasekera CJ, Gunathilaka N, Menike C, Anpahalan P, Perera N, de Silva NR et al.. Detection of human strongyloidiasis among patients with a high risk of complications attending selected tertiary care hospitals in Colombo, Sri Lanka using molecular and serological diagnostic tools. Parasites & vectors 2024. link 5 Weitzel T, Dittrich S, Mockenhaupt FP, Lindner AK. Serological diagnosis of strongyloidiasis: An evaluation of three commercial assays. PLoS neglected tropical diseases 2024. link 6 Wongphutorn P, Noordin R, Anuar NS, Worasith C, Kopolrat KY, Homwong C et al.. Examination of Diagnostic Performance of New IgG4 Rapid Test Compared with IgG- and IgG4-ELISAs to Investigate Epidemiology of Strongyloidiasis in Northeast Thailand. The American journal of tropical medicine and hygiene 2024. link 7 Eamudomkarn C, Ruantip S, Sithithaworn J, Techasen A, Kopoolrat KY, Worasith C et al.. Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand. PloS one 2023. link 8 Crego-Vicente B, Fernández-Soto P, García-Bernalt Diego J, Febrer-Sendra B, Muro A. Development of a Duplex LAMP Assay with Probe-Based Readout for Simultaneous Real-Time Detection of Schistosoma mansoni and Strongyloides spp. -A Laboratory Approach to Point-Of-Care. International journal of molecular sciences 2023. link 9 Autier B, Boukthir S, Degeilh B, Belaz S, Dupuis A, Chevrier S et al.. Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. Parasite (Paris, France) 2021. link 10 Tamarozzi F, Longoni SS, Mazzi C, Pettene S, Montresor A, Mahanty S et al.. Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. Parasites & vectors 2021. link 11 Masoori L, Meamar AR, Bandehpour M, Hemphill A, Razmjou E, Mokhtarian K et al.. Fatty acid and retinol-binding protein: A novel antigen for immunodiagnosis of human strongyloidiasis. PloS one 2019. link 12 Gétaz L, Castro R, Zamora P, Kramer M, Gareca N, Torrico-Espinoza MDC et al.. Epidemiology of Strongyloides stercoralis infection in Bolivian patients at high risk of complications. PLoS neglected tropical diseases 2019. link 13 Ruantip S, Eamudomkarn C, Techasen A, Wangboon C, Sithithaworn J, Bethony JM et al.. Accuracy of Urine and Serum Assays for the Diagnosis of Strongyloidiasis by Three Enzyme-Linked Immunosorbent Assay Protocols. The American journal of tropical medicine and hygiene 2019. link 14 Ngui R, Halim NA, Rajoo Y, Lim YA, Ambu S, Rajoo K et al.. Epidemiological Characteristics of Strongyloidiasis in Inhabitants of Indigenous Communities in Borneo Island, Malaysia. The Korean journal of parasitology 2016. link 15 Luvira V, Trakulhun K, Mungthin M, Naaglor T, Chantawat N, Pakdee W et al.. Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients. The American journal of tropical medicine and hygiene 2016. link 16 Corral MA, Paula FM, Gottardi M, Meisel DM, Castilho VL, Gonçalves EM et al.. IMMUNODIAGNOSIS OF HUMAN STRONGYLOIDIASIS: USE OF SIX DIFFERENT ANTIGENIC FRACTIONS FROM Strongyloides venezuelensis PARASITIC FEMALES. Revista do Instituto de Medicina Tropical de Sao Paulo 2015. link 17 Paula FM, Malta Fde M, Marques PD, Sitta RB, Pinho JR, Gryschek RC et al.. Molecular diagnosis of strongyloidiasis in tropical areas: a comparison of conventional and real-time polymerase chain reaction with parasitological methods. Memorias do Instituto Oswaldo Cruz 2015. link 18 Sithithaworn J, Sithithaworn P, Janrungsopa T, Suvatanadecha K, Ando K, Haswell-Elkins MR. Comparative assessment of the gelatin particle agglutination test and an enzyme-linked immunosorbent assay for diagnosis of strongyloidiasis. Journal of clinical microbiology 2005. link 19 Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T et al.. Distribution of lymphocyte subsets in healthy human immunodeficiency virus-negative adult Ethiopians from two geographic locales. Clinical and diagnostic laboratory immunology 2001. link 20 Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Eitan S, Stein M et al.. Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection. Clinical and experimental immunology 1998. link 21 Genta RM, Frei DF, Linke MJ. Demonstration and partial characterization of parasite-specific immunoglobulin A responses in human strongyloidiasis. Journal of clinical microbiology 1987. link 22 Albermann S, Vischer A, Vu XL, Horat A, Grimm F, Nickel B et al.. Serodiagnosis of strongyloidiasis in a low-endemic setting - a two-tiered test approach. Travel medicine and infectious disease 2025. link 23 Corral MA, Meisel DMCL, Gouvêa MSG, Pessoa MG, Abdala E, Terrabuio DRB et al.. Detection of Anti-Strongyloides Antibodies in the Serum of Liver Transplant Recipients: Need of Screening for This Neglected Helminthiasis. Parasite immunology 2024. link 24 Gonzaga HT, Mendonça SCL, Gonçalves ALR, Ferreira-Júnior Á, Rodrigues RM, Gonçalves-Pires MDRF et al.. IgG4 and IgE anti-Strongyloides stercoralis as additional parameters in characterizing patients with diabetes from a hyperendemic area. Diagnostic microbiology and infectious disease 2023. link 25 Corral MA, Gonçalves ALR, Costa IN, Abdala E, Pierrotti LC, Chieffi PP et al.. Immune complexes as a tool for strongyloidiasis immunodiagnosis in kidney and liver transplant candidate. Parasite immunology 2022. link 26 Bosqui LR, Corral MA, Levy D, Bydlowski SP, Gryschek RCB, Custodio LA et al.. Evaluation of the Dot-ELISA as a diagnostic test for human strongyloidiasis based on the detection of IgA in saliva. Acta tropica 2020. link 27 de Faria LS, de Souza DLN, Ribeiro RP, de Sousa JEN, Borges IP, Ávila VMR et al.. Highly specific and sensitive anti-Strongyloides venezuelensis IgY antibodies applied to the human strongyloidiasis immunodiagnosis. Parasitology international 2019. link 28 Nunes JB, Emídio TCO, Marques MJ, Caldas IS, Souza RLM, Kanamura HY et al.. Seroepidemiological aspects of human infection by Strongyloides stercoralis in Alfenas, southern Minas Gerais, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2018. link 29 Fradejas I, Herrero-Martínez JM, Lizasoaín M, Rodríguez de Las Parras E, Pérez-Ayala A. Comparative study of two commercial tests for Strongyloides stercoralis serologic diagnosis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2018. link 30 Gonçalves AAS, Lopes CA, Gonzaga HT, Gonçalves ALR, Levenhagen MA, Oliveira LCM et al.. Detection of immune complexes and evaluation of alcoholic individuals' serological profile in the diagnosis of strongyloidiasis. Parasitology international 2018. link 31 Bosqui LR, Gonçalves ALR, Gonçalves-Pires MRF, Pavanelli WR, Conchon-Costa I, Costa-Cruz JM et al.. Immune complex detection in saliva samples: an innovative proposal for the diagnosis of human strongyloidiasis. Parasitology 2018. link 32 Bosqui LR, Gonzaga HT, Gonçalves-Pires MDRF, de Paula FM, Almeida RS, Pavanelli WR et al.. Avidity as a criterion for diagnosis of human strongyloidiasis increases specificity of IgG ELISA. Diagnostic microbiology and infectious disease 2017. link 33 Gottardi M, Paula FM, Corral MA, Meisel DM, Costa SF, Abdala E et al.. Immunofluorescence assay for diagnosis of strongyloidiasis in immunocompromised patients. Infectious diseases (London, England) 2015. link 34 Nielsen MK, Vidyashankar AN, Gravatte HS, Bellaw J, Lyons ET, Andersen UV. Development of Strongylus vulgaris-specific serum antibodies in naturally infected foals. Veterinary parasitology 2014. link 35 Shollenberger LM, Bui CT, Paterson Y, Nyhoff L, Harn DA. HIV-1 vaccine-specific responses induced by Listeria vector vaccines are maintained in mice subsequently infected with a model helminth parasite, Schistosoma mansoni. Vaccine 2013. link 36 Gonçalves AL, Rocha CA, Gonzaga HT, Gonçalves-Pires Mdo R, Ueta MT, Costa-Cruz JM. Specific IgG and IgA to larvae, parthenogenetic females, and eggs of Strongyloides venezuelensis in the immunodiagnosis of human strongyloidiasis. Diagnostic microbiology and infectious disease 2012. link 37 Paula FM, Costa-Cruz JM. Epidemiological aspects of strongyloidiasis in Brazil. Parasitology 2011. link 38 El-Badry AA. ELISA-based coproantigen in human strongyloidiaisis: a diagnostic method correlating with worm burden. Journal of the Egyptian Society of Parasitology 2009. link 39 Stothard JR, Pleasant J, Oguttu D, Adriko M, Galimaka R, Ruggiana A et al.. Strongyloides stercoralis: a field-based survey of mothers and their preschool children using ELISA, Baermann and Koga plate methods reveals low endemicity in western Uganda. Journal of helminthology 2008. link 40 Huaman MC, Sato Y, Aguilar JL, Terashima A, Guerra H, Gotuzzo E et al.. Gelatin particle indirect agglutination and enzyme-linked immunosorbent assay for diagnosis of strongyloidiasis using Strongyloides venezuelensis antigen. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003. link80017-2) 41 Machado ER, Ueta MT, de Fátima Gonçalves-Pires Mdo R, Alves de Oliveira JB, Faccioli LH, Costa-Cruz JM. Strongyloides venezuelensis alkaline extract for the diagnosis of human strongyloidiasis by enzyme-linked immunosorbent assay. Memorias do Instituto Oswaldo Cruz 2003. link 42 Atkins NS, Conway DJ, Lindo JF, Bailey JW, Bundy DA. L3 antigen-specific antibody isotype responses in human strongyloidiasis: correlations with larval output. Parasite immunology 1999. link 43 Neva FA, Filho JO, Gam AA, Thompson R, Freitas V, Melo A et al.. Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. The Journal of infectious diseases 1998. link 44 Bahirathan M, Miller JE, Barras SR, Kearney MT. Susceptibility of Suffolk and Gulf Coast Native suckling lambs to naturally acquired strongylate nematode infection. Veterinary parasitology 1996. link00969-7) 45 Rossi CL, Takahashi EE, Partel CD, Teodoro LG, da Silva LJ. Total serum IgE and parasite-specific IgG and IgA antibodies in human strongyloidiasis. Revista do Instituto de Medicina Tropical de Sao Paulo 1993. link 46 Genta RM. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. American journal of clinical pathology 1988. link 47 Gam AA, Neva FA, Krotoski WA. Comparative sensitivity and specificity of ELISA and IHA for serodiagnosis of strongyloidiasis with larval antigens. The American journal of tropical medicine and hygiene 1987. link 48 Genta RM, Weesner R, Douce RW, Huitger-O'Connor T, Walzer PD. Strongyloidiasis in US veterans of the Vietnam and other wars. JAMA 1987. link 49 Carvalho EM, Andrade TM, Andrade JA, Rocha H. Immunological features in different clinical forms of strongyloidiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1983. link90162-1) 50 Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Transactions of the Royal Society of Tropical Medicine and Hygiene 1982. link90034-7)

Infection by Strongyloides